# Interferon beta-1a

## Rebif inj 44mcg

| 藥物代碼           | IREB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 副作用             | >10%:Headache (58% to 70%), fatigue (33% to 41%), depression (18% to 25%), pain (23%), chills (19%), dizziness (14%), Nausea (23%), abdominal pain (8% to 22%), Urinary tract infection (17%), Leukopenia (28% to 36%), lymphadenopathy (11% to 12%), Increased serum ALT (20% to 27%), increased serum AST (10% to 17%), Antibody development (neutralizing; significance not known; Rebif: 24% to 31%; Avonex: 5%), Injection site reaction (3% to 92%), Myalgia (25% to 29%), back pain (23% to 25%), weakness (24%), skeletal pain (10% to 15%), rigors (6% to 13%), Visual disturbance (7% to 13%), Flu-like symptoms (49% to 59%), sinusitis (14%), upper respiratory tract infection (14%), Fever (20% to 28%)1% to 10%:Chest pain (5% to 8%), vasodilation (2%), Hypertonia (6% to 7%), migraine (5%), ataxia (4% to 5%), drowsiness (4% to 5%), malaise (4% to 5%), seizure (1% to 5%), suicidal tendencies (4%)Dermatologic: Erythematous rash (5% to 7%), maculopapular rash (4% to 5%), alopecia (4%), hyperhidrosis (4%), urticaria, Thyroid disease (4% to 6%), Xerostomia (1% to 5%), toothache (3%), Urinary frequency (2% to 7%), urinary incontinence (2% to 4%), urine abnormality (3%), Thrombocytopenia (2% to 8%), anemia (3% to 5%), Hyperbilirubinemia (2% to 3%), Infection (7%), Pain at injection site (8%), bruising at injection site (6%), inflammation at injection site (6%), tissue necrosis at injection site (1% to 3%), Arthralgia (9%), Eye disease (4%), xerophthalmia (1% to 3%), Bronchitis (8%) |
| 禁忌               | pregnancy, People currently with severe depression and / or suicidal tendency, Hypersensitivity to natural or recombinant interferon beta or any other component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 藥物保存方式       | 2 °C – 8°C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 用法用量           | Initial: 8.8 mcg 3 times weekly on week 1-2. Titration: 22 mcg 3 times weekly on week 3-4. Target dose: 44 mcg 3 times weekly after week 5. target dose may be decreased to 22mcg if necessary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 附帶說明           | [仿單]數據指出，於受孕前或妊娠第一期時暴露於 interferon beta， 其發生重大先天性異常的風險並未增加。收集數據時 interferon beta 尚屬懷孕期間之使用禁忌，在檢測出/或確認懷孕後可能會中斷治療，因此無法確定在妊娠第一期的暴露時間，而暴露於妊娠第二期及第三期的經驗非常有限。 依據動物試驗數據，自發性流產的風險可能會增加。 然而依據目前可獲得的數據，尚無法充分評估暴露於interferon beta 的孕婦其自發性流產的風險，但目前該數據並未顯示有增加的風險。 如有臨床需要，可以在懷孕期間考慮使用 Rebif。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 哺乳期用藥建議     | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 附帶說明           | [仿單] 關於 interferon beta-1a 是否會分佈到母乳中，目前可獲得的資訊有限。 若一併考量interferon beta 的化學/生理學特性，則乳汁中分泌的 interferon beta-1a 濃度應很低。 哺乳的效益及可能風險應與病人對於 interferon beta-1a 治療的臨床需求一併考量。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 注射劑給藥建議途徑 | SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 注意事項           | 單次使用。只有澄清至乳白色溶液、無顆粒、無可見變質跡象的注射液才可使用。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

